Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Myosin phosphatase isoform switching in vascular smooth muscle development.

Payne MC, Zhang HY, Prosdocimo T, Joyce KM, Koga Y, Ikebe M, Fisher SA.

J Mol Cell Cardiol. 2006 Feb;40(2):274-82. Epub 2005 Dec 13.

PMID:
16356512
2.

Dynamic changes in expression of myosin phosphatase in a model of portal hypertension.

Payne MC, Zhang HY, Shirasawa Y, Koga Y, Ikebe M, Benoit JN, Fisher SA.

Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1801-10. Epub 2004 Jan 2.

3.

Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation.

Khatri JJ, Joyce KM, Brozovich FV, Fisher SA.

J Biol Chem. 2001 Oct 5;276(40):37250-7. Epub 2001 Aug 2.

4.

Conditioning effect of blood flow on resistance artery smooth muscle myosin phosphatase.

Zhang H, Fisher SA.

Circ Res. 2007 Mar 16;100(5):730-7. Epub 2007 Feb 9.

5.

Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation.

Chen FC, Ogut O, Rhee AY, Hoit BD, Brozovich FV.

J Mol Cell Cardiol. 2006 Sep;41(3):488-95. Epub 2006 Jul 3.

PMID:
16815432
6.

Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy.

Lu Y, Zhang H, Gokina N, Mandala M, Sato O, Ikebe M, Osol G, Fisher SA.

Am J Physiol Cell Physiol. 2008 Feb;294(2):C564-71. Epub 2007 Dec 19.

7.

MYPT1 protein isoforms are differentially phosphorylated by protein kinase G.

Yuen S, Ogut O, Brozovich FV.

J Biol Chem. 2011 Oct 28;286(43):37274-9. doi: 10.1074/jbc.M111.282905. Epub 2011 Sep 2.

8.

Redox signaling and splicing dependent change in myosin phosphatase underlie early versus late changes in NO vasodilator reserve in a mouse LPS model of sepsis.

Reho JJ, Zheng X, Asico LD, Fisher SA.

Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1039-50. doi: 10.1152/ajpheart.00912.2014. Epub 2015 Feb 27.

9.

Vascular reactivity in heart failure: role of myosin light chain phosphatase.

Karim SM, Rhee AY, Given AM, Faulx MD, Hoit BD, Brozovich FV.

Circ Res. 2004 Sep 17;95(6):612-8. Epub 2004 Aug 19.

11.

Myosin phosphatase: structure, regulation and function.

Ito M, Nakano T, Erdodi F, Hartshorne DJ.

Mol Cell Biochem. 2004 Apr;259(1-2):197-209. Review.

PMID:
15124925
12.

Spontaneously tonic smooth muscle has characteristically higher levels of RhoA/ROK compared with the phasic smooth muscle.

Patel CA, Rattan S.

Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G830-7. Epub 2006 Jun 8.

13.

Myosin phosphatase-Rho interacting protein. A new member of the myosin phosphatase complex that directly binds RhoA.

Surks HK, Richards CT, Mendelsohn ME.

J Biol Chem. 2003 Dec 19;278(51):51484-93. Epub 2003 Sep 23.

14.

A myosin phosphatase targeting subunit isoform transition defines a smooth muscle developmental phenotypic switch.

Dirksen WP, Vladic F, Fisher SA.

Am J Physiol Cell Physiol. 2000 Mar;278(3):C589-600.

15.

M-RIP targets myosin phosphatase to stress fibers to regulate myosin light chain phosphorylation in vascular smooth muscle cells.

Surks HK, Riddick N, Ohtani K.

J Biol Chem. 2005 Dec 30;280(52):42543-51. Epub 2005 Oct 28.

16.

TRA2β controls Mypt1 exon 24 splicing in the developmental maturation of mouse mesenteric artery smooth muscle.

Zheng X, Reho JJ, Wirth B, Fisher SA.

Am J Physiol Cell Physiol. 2015 Feb 15;308(4):C289-96. doi: 10.1152/ajpcell.00304.2014. Epub 2014 Nov 26.

17.

Telokin mediates Ca2+-desensitization through activation of myosin phosphatase in phasic and tonic smooth muscle.

Choudhury N, Khromov AS, Somlyo AP, Somlyo AV.

J Muscle Res Cell Motil. 2004;25(8):657-65. Epub 2005 Feb 24.

PMID:
15750850
18.

Characterization and function of MYPT2, a target subunit of myosin phosphatase in heart.

Okamoto R, Kato T, Mizoguchi A, Takahashi N, Nakakuki T, Mizutani H, Isaka N, Imanaka-Yoshida K, Kaibuchi K, Lu Z, Mabuchi K, Tao T, Hartshorne DJ, Nakano T, Ito M.

Cell Signal. 2006 Sep;18(9):1408-16. Epub 2006 Jan 23.

PMID:
16431080
19.

Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits.

Eto M, Kitazawa T, Brautigan DL.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8888-93. Epub 2004 Jun 7.

20.

Supplemental Content

Support Center